Showing results (81-90 of 226) with videos related to
Sort By:
Pageof 23
JCO Precision Oncology|February 27, 2024
Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome SpectrumCristina Fortuno, Bing-Jian Feng, Courtney Carroll, et al.Brain Research|July 1, 2005
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicityDavid M Thomas, Donald M KuhnClinical Sarcoma Research|May 17, 2012
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumoursFergal C Kelleher, David M ThomasMolecular & Cellular Oncology|June 17, 2016
The life history of neochromosomes revealedAnthony T Papenfuss, David M ThomasCurrent Oncology Reports|April 20, 2011
Novel approaches to treatment of leiomyosarcomasIan M Collins, David M ThomasThe Journal of Pharmacology and Experimental Therapeutics|February 19, 2005
Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicityDavid M Thomas, Donald M KuhnJournal of Neurochemistry|February 3, 2005
Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamineDavid M Thomas, Donald M KuhnJournal of the National Comprehensive Cancer Network : JNCCN|June 29, 2010
Specific targets in sarcoma and developmental therapeuticsDavid M Thomas, Andrew J WagnerSarcoma|January 22, 2011
Liposarcoma: molecular genetics and therapeuticsRachel Conyers, Sophie Young, David M ThomasPageof 23